A recent study on a new monoclonal antibody to prevent Clostridium difficile infection is available from the NEJM. Here’s the link: Preventing Clostridium difficile Infection Recurrence
My take: In Modify I and Modify II, Bezlotoxumab reduced the rate of Clostridium difficile recurrence in elderly patients (median age 66 years). In a high risk patients, the likely hefty cost of this medication may be warranted.
These studies were likely pivotal in receiving FDA approval: FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection